N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 26 NOK 3.17% Market Closed
Market Cap: 623.5m NOK

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is 61.58 NOK. Compared to the current market price of 26 NOK, Navamedic ASA is Undervalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVA Relative Value
Base Case
61.58 NOK
Undervaluation 58%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
76
Median 3Y
1.5
Median 5Y
2
Industry
2.6
Forward
1.1
vs History
vs Industry
0
Median 3Y
20.2
Median 5Y
13.6
Industry
21.6
Forward
-45.5
vs History
60
vs Industry
37
Median 3Y
24.3
Median 5Y
23
Industry
16.5
vs History
vs Industry
29
Median 3Y
10.9
Median 5Y
10.8
Industry
22.5
vs History
73
vs Industry
45
Median 3Y
3.4
Median 5Y
3.7
Industry
2.3
vs History
77
vs Industry
76
Median 3Y
1.7
Median 5Y
2
Industry
2.9
Forward
1.1
vs History
76
vs Industry
70
Median 3Y
4.3
Median 5Y
4.9
Industry
5.5
vs History
76
vs Industry
27
Median 3Y
15.8
Median 5Y
18.3
Industry
13
Forward
12.7
vs History
23
vs Industry
32
Median 3Y
23.7
Median 5Y
24.1
Industry
16.6
Forward
35.3
vs History
60
vs Industry
36
Median 3Y
25.2
Median 5Y
22.4
Industry
15.8
vs History
46
vs Industry
30
Median 3Y
21
Median 5Y
14.7
Industry
19.1
vs History
74
vs Industry
54
Median 3Y
2
Median 5Y
2.6
Industry
1.9

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Navamedic ASA
OSE:NAVA
623.5m NOK 1.2 -18.8 9.4 30.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.6 39.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
515.3B USD 5.6 20.5 16.8 21.7
CH
Roche Holding AG
SIX:ROG
256.3B CHF 4.2 27.2 11.6 13.6
UK
AstraZeneca PLC
LSE:AZN
211.1B GBP 4.9 30 108.3 158.4
CH
Novartis AG
SIX:NOVN
205.8B CHF 4.6 18 11.4 14.7
US
Merck & Co Inc
NYSE:MRK
249.4B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.5 11
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
150.3B USD 2.4 15.3 7.7 10.5
P/E Multiple
Earnings Growth PEG
NO
N
Navamedic ASA
OSE:NAVA
Average P/E: 24
Negative Multiple: -18.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBITDA: 399.8
9.4
17%
0.6
US
Eli Lilly and Co
NYSE:LLY
36.6
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.8
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 713.1
30.8
30%
1
US
Eli Lilly and Co
NYSE:LLY
39.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.7
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3